Merck & Co Inc (MRK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH6319D

Download Sample Report download

Buy the Full ReportStarting from $250

Published on

November 2018

Total pages

458

About the Report

Summary

Merck & Co Inc (Merck) is a biopharmaceutical company that focuses on the discovery, development, manufacture and commercialization of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for treating cardiovascular, cancer, immune disorders, infectious, respiratory and women's diseases, and diabetes. The company provides animal health products including vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. Outside the US, the company operates through subsidiaries. It operates in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

Merck & Co Inc (MRK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Merck & Co Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents 3

List of Tables 11

List of Figures 16

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 17

Merck & Co Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 18

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 19

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 20

Merck & Co Inc, Medical Devices Deals, 2012 to YTD 2018 22

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 23

Merck & Co Inc, Pharmaceuticals & Healthcare, Deal Details 38

Asset Purchase 38

Hypermarcas To Sell Rights To Manufacture Medicines To MSD Brazil Investments For USD 31 Million 38

Venture Financing 39

Moderna Therapeutics Raises USD125 Million in Series H Preferred Equity Financing 39

Rigontec Raises Additional USD16.7 Million in Series A Financing 40

Just Biotherapeutics Raises USD14 Million in Series A2 Financing 42

Just Biotherapeutics Raises USD15 Million in Series A Financing Round 44

RaNA Therapeutics Raises USD55 Million in series B Financing 45

Afferent Pharma Raises USD55 Million in Series C Financing 46

Gladius Pharma Raises USD3.3 Million in Series A Financing 47

Rigontec Raises Additional USD5.21 Million in Series A Financing 48

NGM Biopharma Raises USD106 Million in Series E Financing 49

EnGene Raises USD11 Million in Series B Venture Financing 50

OsteoQC Raises Funds through Seed Financing 51

Rigontec Raises USD12 Million in Series A Venture Financing 52

ImaginAb Raises USD21 Million in Series B Venture Financing 53

AdvanDx Raises USD 12 Million In Series B-1 Venture Financing 54

HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 55

OncoEthix Raises USD 19 Million In Series B Financing 56

Aviir Raises USD 20 Million In Venture Financing 58

Afferent Pharmaceuticals Secures USD5 Million in Venture Funding Round 60

cCAM Biotherapeutics Raises USD 6 Million In Series A Financing 61

Afferent Pharmaceuticals Secures USD5 Million in Venture Funding 62

Partnerships 63

Antigen Express Enters into Agreement with Merck for KEYTRUDA 63

CogState Enters Into Licensing Agreement With Merck Canada For Cognition Test 64

FLX Bio Enters into Agreement with Merck 65

Eisai and MSD Enter into Co-Marketing Agreement 66

eFFECTOR Therapeutics Enters into Agreement with Merck 67

Dragonfly Therapeutics Enters into Collaboration Agreement with Merck 68

Daiichi Sankyo Enters into Co-Development Agreement with Merck Sharp & Dohme 69

IMV Enters into Partnership with Merck 70

IRBM Science Park Enters into Collaboration Agreement with Merck 71

University of Western Australia and Merck Enter into Research Partnership 72

Rexahn Pharma Enters into Clinical Trial Collaboration Agreement with Merck 73

4D pharma Enters into Agreement with Merck 74

MSD Enters into Distribution Agreement with Kyorin Pharma 75

OncoSec Medical Enters into Agreement with Merck 76

IO Biotech Enters into Clinical Trial Collaboration Agreement with Merck 77

Immutep Enters into Clinical Trial Collaboration and Supply Agreement with Merck 78

Eisai Enters into Co-Development and Co-Commercialization Agreement with Merck 79

Merck to Enter into Agreement with Schneider Electric 80

PharmAbcine Enters into Agreement with Merck 81

Parkinson's Institute and Clinical Center Enters into Agreement with Merck 82

Grunenthal Enters into Distribution Agreement with Merck 83

Astellas Pharma Enters into Co-Promotion Agreement with MSD 84

Aeglea BioTherapeutics Enters into Agreement with Merck 85

KalVista Pharma Enters into Agreement with Merck 86

SELLAS Life Sciences Enters into Clinical Trial Agreement with Merck 87

Eisai Enters into Agreement with Merck for Eribulin 88

Eisai Enters into Agreement with Merck 89

AstraZeneca Enters into Agreement with Merck 90

Invenra Enters into Agreement With Merck 91

PDS Biotech Enters into Agreement with Merck 92

Leap Therapeutics Enters into Agreement with Merck International 93

Aduro Biotech Expands Agreement with Merck 94

OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 95

Array BioPharma Enters into Agreement with Merck 96

Atara Biotherapeutics Enters into Agreement with Merck 97

HitGen Expands Agreement with Merck 98

BerGenBio Enters into Agreement with Merck 99

Stratophase Enters into Agreement with Merck 100

CMIC Enters into Agreement with MSD for Diazoxide 101

Ramot at Tel Aviv University Enters into Research Agreement with Merck 102

NOXXON Pharma Enters into Agreement with Merck 103

Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 104

Proteros biostructures Enters into Agreement with Merck Sharp & Dohme 105

Genexine Enters into Clinical Research Agreement with Merck 106

Adaptimmune Therapeutics Enters into Clinical Trial Agreement with Merck for Keytruda 107

Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 108

Merck Enters into Distribution Agreement with JenKem Tech 109

MSD Enters into Agreement with Kyorin Pharma 110

Agency for Science, Technology and Research Enters into Agreement with Merck 111

Menarini Asia-Pacific Enters into Agreement with Merck 112

Innovative Targeting Solutions Enters into Research Agreement with Merck 113

Fujifilm Diosynth Biotech Partners with Merck 114

Merck Enters into Co-Promotion Agreement with Taiho Pharma for Pembrolizumab 115

Myriad Genetics Enters into Research Agreement with Tesaro and Merck 116

Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 117

ImmunoGen Enters into Research Agreement with Merck 118

Merck Enters into Agreement with AbCellera Biologics 119

Affimed Enters into Research Agreement with Merck 120

BioLineRx Expands Licensing Agreement with Merck 121

Quartet Medicine Enters into Agreement with Merck 122

Complix Expands Agreement with Merck 123

Eli Lilly Expands its Agreement with Merck 124

Merck Enters into Agreement with Akeso Biopharma 125

Amgen and Merck Enter into Agreement 126

Viralytics Enters into Agreement with Merck 127

GlaxoSmithKline Partners with Merck 128

Synthace Enters into Agreement with Merck 129

MacroGenics Enters into Agreement with Merck 130

Incyte Extends Partnership with Merck 131

Proteros Enters Into an Agreement with Merck Sharp and Dohme 132

Merck Enters into Agreement with OBI Pharma 133

Merck Enters into Agreement with DNAtrix 134

Merck Enters into Research Agreement with University of Texas MD Anderson Cancer Center 135

Immune Design Enters into Clinical Collaboration Agreement with Merck 136

Laboratorios Farmaceuticos Rovi Enters into Co-Marketing Agreement with Merck Sharp & Dohme for Orvatez 137

Plexxikon Enters into Agreement with Merck 138

PeptiDream Enters into Peptide Discovery Agreement with Merck 139

Organovo Enters into Research Agreement with Merck Sharp & Dohme 140

Syndax Pharma Expands its Agreement with Merck 141

Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 142

NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 143

Merck Expands Agreement with Eli Lilly 144

Enumeral Biomedical Amends Agreement with Merck Sharp & Dohme 145

Kyorin Pharma Amends Co-Marketing Agreement with MSD 146

Bind Therapeutics Enters into R&D Agreement with Merck 147

Advaxis Enters into Agreement with Merck 148

Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 149

Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 150

Hanmi Pharma Enters into Co-promotion Agreement with Merck Sharp & Dohme Korea 151

Dako Enters Into Co-Development Agreement With Merck 152

Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 153

Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 154

Optimer Pharma Extends Co-Promotion Agreement With Cubist Pharma For Dificid 156

Abide Therapeutics Enters Into Co-Development Agreement With Merck 157

Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 158

Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 159

Lycera Enters Into Research Agreement With Merck To Develop Novel Treatments For Autoimmune Diseases 160

Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 161

Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 162

ActoGeniX Enters Into Research Agreement With Merck 163

TPP Global Development Enters Into Agreement With Sprint Biosciences To Develop Choline Kinase Inhibitors 164

Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 165

ALK Enters Into Co-Promotion Agreement With MSD For Grazax 166

Redbiotec Extends Drug Discovery Agreement With Merck 168

Merck Forms Joint Venture With Supera Farma Laboratorios 169

MSD Enters Into Distribution Agreement With Julphar 170

AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 171

Fundacion Medina Enters Into Research Agreement With Cubist Pharma 172

Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 173

MSD India Plans Co-Marketing Agreement For Diabetes Drugs 174

Licensing Agreements 175

Perrigo Enters into Licensing Agreement with Merck 175

Merck Enters into Licensing Agreement with Sutro Biopharma 176

Prokaryotics Enters into Licensing Agreement with Merck 177

Merck Enters into Licensing Agreement with Institute of Cancer Research and Cancer Research UK 178

Merck Enters into Licensing Agreement with Cue Biopharma 179

Dongwha Pharm Enters into Licensing Agreement with Merck 180

Merck Enters into Licensing And Option Agreement with AIMM Therapeutics 181

Merck Enters into Licensing Agreement with Teijin Pharma 182

Kyorin Pharma Enters into Licensing Agreement with Merck 183

Urovant Sciences Enters into Licensing Agreement with Merck Sharp & Dohme 184

Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 185

Ascentage Pharma Enters into Licensing Agreement with Merck 186

Merck Expands Licensing Agreement with Moderna Therapeutics 187

Merck Enters into Licensing Agreement with Harvard University 189

Merck Enters into Licensing Agreement with AureoGen Biosciences 190

Merck Enters into Licensing Agreement with Cancer Research Technology 191

Adimab Enters into Licensing Agreement with Merck 192

Merck Enters into Licensing Agreement with Selvita 193

Merck Enters into Licensing Agreement with Codexis for CodeEvolver Platform Technology 194

Allergan Enters into Licensing Agreement with Merck 196

Merck Extends Licensing Agreement with Agenus 197

Arvinas Enters into Licensing Agreement with Merck 198

Moderna Therapeutics Amends Terms of Licensing Agreement with Merck 199

Merck Enters into Licensing Agreement with BioNovion 200

Zymeworks Extends Licensing Agreement with Merck 201

Merck Enters into Licensing Agreement with NewLink Genetics 202

Euroscreen Enters into Licensing Agreement with Merck 204

Sun Pharma Enters into Licensing Agreement with Merck 205

Kyorin Pharma Enters into Licensing Agreement with Merck 206

Bionomics Enters into Licensing Agreement with Merck for BNC375 207

Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 208

Gulf Pharma Enters into Licensing Agreement with MSD 209

Gulf Pharmaceutical Industries (Julphar) Enters into Licensing Agreement with Merck 210

NanoBio Enters Into Licensing Agreement With Merck 211

Merck Expands Licensing Agreement with Ablynx 212

ARMO Biosciences Enters into Licensing Agreement with Merck 214

Bionomics Extends Licensing Agreement with Merck 215

Xencor Enters Into Licensing Agreement With Merck 216

Cerecor Enters Into Licensing Agreement With Merck For MK-0657 217

Meiji Seika Pharma Enters into Licensing Agreement with MSD 218

Merck Enters into Licensing Agreement with Ra Pharma 219

Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane 221

Microbiotix Enters Into Licensing Agreement With Merck For MBX-700 And MBX-701 222

Menlo Therapeutics Enters into Licensing Agreement with Merck 223

Merck Enters Into Licensing Agreement With GE Healthcare For Flutemetamol 224

Theravance Enters Into Licensing Agreement With Merck For Cardiovascular Therapeutic Candidates 225

Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 226

MultiVir Enters into Licensing Agreement with Merck Sharp & Dohme 227

R-Pharm Enters Into Licensing Agreement With Merck For Narlaprevir 228

Ambrx Enters Into Licensing Agreement With Merck For Site Specific Protein Medicinal Chemistry Technology 229

Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 230

Merck Enters into Licensing Agreement with Medicines Patent Pool 231

EnWave Enters into Licensing Agreement with Merck 232

Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 233

Polyplus-transfection Enters Into Licensing Agreement With Merck 235

AstraZeneca Enters Into Licensing Agreement With Merck For MK-1775 236

Merck Enters Into Licensing Agreement With Lupin 238

Hawaii Biotech Enters Into Licensing Agreement With Merck For West Nile Vaccine Technology 239

Acerta Pharma Enters into Licensing Agreement with Merck Sharp & Dohme 240

Netherlands Translational Research Center Enters Into Licensing Agreement With Merck 241

Delphi Genetics Enters Into Licensing Agreement With Merck For StabyExpress Technology 242

Merck Enters Into Licensing Agreement With Yamasa For EFdA 243

Merck Enters Into Licensing Agreement With Numerate For In Silico Drug Design Technology 244

Merck Extends Licensing Agreement with Codexis 245

Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 246

Equity Offering 247

Bionomics Raises USD9 Million in Private Placement of Shares 247

OpGen Raises USD5 Million in Private Placement of Shares 248

BeiGene Raises USD97.4 Million in Private Placement of Series A-2 Preferred Stock 249

Moderna Therapeutics Raises USD50 Million in Private Placement of Shares 250

BeiGene Raises USD74.5 Million in Private Placement of Series A Preferred Stock 251

Trius Therapeutics Completes Public Offering Of Shares For USD 34 Million 252

Trius Therapeutics Completes Second Tranche Of Private Placement Of Shares For USD 5 Million 253

VirtualScopics Completes First Tranche Of Private Placement Of Shares For USD 3 Million 255

Trius Therapeutics Completes Over-allotment Option Of Underwritten Public Offering For USD 52 Million 256

Debt Offering 258

Merck Plans to Raise Funds through Public Offering of Debt Securities 258

Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 259

Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 260

Merck Completes Public Offering of Notes Due 2020 for USD700 Million 261

Merck Completes Public Offering of Notes Due 2025 for USD2.5 Billion 263

Merck Completes Public Offering of Notes Due 2017 for USD300 Million 265

Merck Completes Public Offering of Notes Due 2045 for USD2 Billion 267

Merck Completes Public Offering of Notes Due 2020 for USD1.25 Billion 269

Merck Completes Public Offering of Notes Due 2022 for USD1.25 Billion 271

Merck Raises USD1.25 Billion in Public Offering of 1.875% Notes Due 2026 273

Merck Raises USD625 Million in Public Offering of 2.5% Notes Due 2034 275

Merck Raises USD1.25 Billion in Public Offering of 1.125% Notes Due 2021 277

Cubist Pharma Completes Private Placement Of Notes Due 2020 For USD 450 Million 279

Cubist Pharma Completes Private Placement Of Notes Due 2018 For USD 350 Million 280

Merck Completes Public Offering Of Notes Due 2016 For USD 500 Million 281

Merck Completes Public Offering Of Notes Due 2016 For USD 1 Billion 283

Merck Completes Public Offering Of Notes Due 2018 For USD 1 Billion 285

Merck Completes Public Offering Of Notes Due 2023 For USD 1.75 Billion 287

Merck Completes Public Offering Of Notes Due 2043 For USD 1.25 Billion 289

Merck Completes Public Offering Of Floating Notes Due 2018 For USD 1 Billion 291

BeiGene Raises USD3 Million in Private Placement of Notes 293

Merck Completes Public Offering Of Notes Due 2042 For USD 500 Million 294

Merck Completes Public Offering Of 1.1% Notes Due 2018 For USD 1 Billion 296

Merck Completes Public Offering Of Notes Due 2022 For USD 1 Billion 298

Asset Transactions 300

Pharmaron Acquires Hoddesdon UK Site from Merck Sharpe & Dohme 300

Aralez Pharma Acquires US and Canadian rights to Zontivity from Merck 301

ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 303

Piramal Enterprises Acquires Five OTC Brands from Organon India and MSD for USD14 Million 304

Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 305

Fareva Acquires La Vallee Manufacturing Site from Merck 306

Merial Acquires Manufacturing Facility from Merck 307

Santen Pharma Acquires Remaining Portfolio of Ophthalmology Products from Merck 308

Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 310

AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 312

KBI Biopharma To Acquire Biologics Operations Of Merck 314

Amphastar Pharmaceuticals Acquires API manufacturing business of Merck 315

Oak Pharma Acquires Tafluprost Business from Merck 316

Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 317

Forest Labs To Acquire US Marketing Rights To Saphris From Merck Sharp & Dohme 318

Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 319

Cerecor Acquires Rights To COMT Inhibitors From Merck 320

Kyorin Acquires Production Facility from MSD 322

Acquisition 323

Merck Acquires Viralytics for USD394 Million 323

Merck Acquires Rigontec 325

Paratek Pharma May Sell Itself 327

Merck Acquires Afferent Pharma 329

Merck Acquires IOmet Pharma 330

Merck Acquires cCAM Biotherapeutics 331

Merck Acquires Cubist Pharma for USD9.5 Billion 332

Merck Acquires OncoEthix for USD375 Million 334

Merck Completes Acquisition of Idenix Pharma for USD3.9 Billion in cash 335

Alnylam Pharma Acquires Sirna Therapeutics From Merck 337

Akorn Acquires Inspire Pharma From Merck For USD 53 Million 338

Cubist Pharma Completes Acquisition of Optimer Pharma for up to USD801 Million 340

Cubist Pharma Completes Acquisition Of Trius Therapeutics For Up To USD 818 Million In A Tender Offer 342

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 344

Merck Plans To Acquire Micro Labs, Maker Of Generic Drugs 346

Merck & Co Inc - Key Competitors 347

Merck & Co Inc - Key Employees 348

Merck & Co Inc - Locations And Subsidiaries 350

Head Office 350

Other Locations & Subsidiaries 350

Joint Venture 372

Recent Developments 374

Strategy And Business Planning 374

Oct 04, 2018: Merck Opens M Lab Collaboration Center in Sao Paulo, Brazil 374

Oct 03, 2018: Merck and Dragonfly partner to develop cancer immunotherapies 375

Nov 27, 2017: MSD announces plan to establish UK Discovery Centre in London 376

Jul 17, 2017: Governor Abbott Announces Merck IT Hub In Austin 377

Mar 02, 2017: Allergopharma Opens new Biopharmaceutical Production in Reinbek 378

Financial Announcements 379

Oct 25, 2018: Merck announces third-quarter 2018 financial results 379

Jul 27, 2018: Merck Announces Second-Quarter 2018 Financial Results 383

May 01, 2018: Merck Announces First-Quarter 2018 Financial Results 387

Oct 27, 2017: Merck Announces Third-Quarter 2017 Financial Results 390

Jul 28, 2017: Merck Announces Second-Quarter 2017 Financial Results 392

May 02, 2017: Merck Announces First-Quarter 2017 Financial Results 395

Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results 397

Corporate Communications 399

Oct 17, 2018: Merck Announces Appointment of Jim Scholefield as Chief Information and Digital Officer 399

Jan 24, 2018: Merck Names Inge Thulin To Board Of Directors 400

Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors 401

Mar 07, 2017: Merck reports positive data from Phase Ib trial of M1095 in psoriasis patients 402

Legal and Regulatory 403

Apr 25, 2018: Fish & Richardson Wins Federal Circuit Affirmance of Reversal of $200 Million Damages Against Gilead After Merck's "Unclean Hands" 403

Feb 19, 2018: Gilead wins reversal in $2.5 billion dispute with Merck 404

Feb 15, 2017: Merck's Wholly Owned Subsidiary Idenix Pharmaceuticals Awarded $2.54 Billion for Infringement of a Hepatitis C Drug Patent 405

Government and Public Interest 406

Oct 16, 2018: Merck Aims to Return to Profitable Growth as of 2019 406

Aug 02, 2018: New method of molecular coupling offers potential to expedite drug discovery process 407

Jul 17, 2018: Merck Announces Future Insight Prize of up to � 1 Million for Groundbreaking Scientific Work 410

Dec 05, 2017: Bioethics International Releases the "Good Pharma Scorecard" in BMJ Open, Ranking the Top 20 Largest Pharmaceutical Companies on Clinical Trial Transparency 411

Oct 19, 2017: Merck Foundation Launches Five-Year Initiative to Improve Diabetes Care for Vulnerable and Underserved U.S. Communities 412

Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal 413

Feb 09, 2017: Merck Foundation Announces Six Program Grant Recipients for Alliance to Advance Patient-Centered Cancer Care 414

Jan 19, 2017: MSD for Mothers Commits $10 Million and Business Expertise to the Global Financing Facility to Help End Preventable Deaths of Mothers 415

Jan 18, 2017: Merck Foundation Grant Expands Project ECHO in Vietnam and India 416

Product News 417

11/21/2017: Medicure Reports Financial Results for Quarter Ended September 30, 2017 417

Oct 29, 2018: Samsung Bioepis riding the biosimilar third wave 419

10/12/2017: Merck Sharp & Dohme receives CHMP positive opinion for Cubicin 420

10/02/2017: Study Published in Nature Reveals Molecular Pathway of Weight-Controlling Hormone, Enabling the Discovery of Multiple Drug Candidates, Including NGM386 for Obesity 421

08/15/2018: Agenus receives second milestone payment from Merck 422

07/17/2017: Cardiome Announces Health Canada Approval of AGGRASTAT High Dose Bolus Regimen 423

07/13/2017: Aduro Announces Milestone Achieved Relating to Collaboration with Merck for Development of Anti-CD27 Antibody for the Treatment of Cancer 424

07/02/2018: Astellas Received Approval for Dafclir Tablets for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan 425

05/03/2017: Rigontec Starts First-In-Human, Phase I/II Trial of RIG-I Agonist RGT100 and Appoints Eugen Leo as Chief Medical Officer 426

04/24/2018: Global Study Published in JAMA Finds Treatment with Lonafarnib Extends Survival in Children with Progeria 427

04/19/2017: Merck to Present Data on Relebactam at ECCMID 2017 428

04/02/2018: Eiger BioPharmaceuticals to Participate in Conferences in April 429

02/16/2017: Antibiotic effective against drug-resistant bacteria in pediatric skin infections 430

Product Approvals 431

Feb 12, 2018: Merck's Cubicin Rejects For Use Within NHS Scotland 431

Jan 23, 2018: Cardiome Announces Expanded Label for Aggrastat in China Including New STEMI Indication and High Dose Bolus Regimen 432

Jul 31, 2017: Astellas Submits Application for Approval of fidaxomicin for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan 433

Clinical Trials 434

Jun 04, 2018: Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018 434

Apr 24, 2018: Merck pits its pneumococcal shot against Pfizer mammoth Prevnar in head-to-head phase 3 435

Apr 17, 2018: Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to �All-Oral� Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress 2018 436

Apr 17, 2018: Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine 437

Mar 21, 2018: Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program 438

Mar 05, 2018: Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors 439

Mar 05, 2018: Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress Meeting 440

Oct 23, 2017: Eiger Presents Data on Lonafarnib at the American Association for the Study of Liver Diseases Meeting 441

Oct 02, 2017: Eiger Announces Presentation on Lonafarnib at the American Association for the Study of Liver Diseases Meeting 442

Jul 06, 2017: Merck to Present Data from on MK-8591 at IAS 2017 443

Apr 21, 2017: Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress 2017 444

Apr 06, 2017: Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting 446

Feb 03, 2017: Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer's Treatment 447

Other Significant Developments 448

Nov 05, 2018: Merck launches Biocontinuum platform for next-generation process improvements 448

Oct 08, 2018: Merck's novel Chemiflex raw materials program solves regulatory compliance challenges in small molecule drug manufacturing 449

Oct 01, 2018: Merck announces �Safer Childbirth Cities� initiative, issues call to action to reverse the rise in U.S. maternal deaths 450

Sep 20, 2018: Merck publishes Corporate Responsibility Report 451

Jul 19, 2018: HHS Secretary Azar Praises Merck's Decision to Cut Drug Prices 452

Nov 13, 2017: PeptiDream Announces 2 nd Milestone from Macrocyclic Peptide Drug Discovery Alliance with Merck & Co., Inc., Kenilworth, N.J., U.S.A 453

Oct 09, 2017: Johnson & Johnson investing $350M in EU biologics operation, adding 200 jobs 454

Jun 22, 2017: Merck and Premier Expand Collaboration to Address Chronic Care and Vaccination Rates 455

Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Merck 456

Feb 16, 2017: Merck's Fight Against Infectious Disease Goes Digital with Launch of ILUM Health Solutions 457

Appendix 458

Methodology 458

About GlobalData 458

Disclaimer 458

List of Figure

List of Figures

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 17

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 18

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 19

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 20

Merck & Co Inc, Medical Devices Deals, 2012 to YTD 2018 22

List of Table

List of Tables

Merck & Co Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 17

Merck & Co Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 18

Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 19

Merck & Co Inc, Deals By Therapy Area, 2012 to YTD 2018 20